Does Network Health Cover Eliquis?

What Eliquis Is and Why Coverage Matters

Eliquis (apixaban) is a Factor Xa inhibitor that reduces blood clot formation without requiring the routine blood monitoring associated with warfarin. The FDA approved apixaban in December 2012 for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation, and subsequent approvals expanded its indications to include deep vein thrombosis (DVT) and pulmonary embolism (PE) treatment.

The drug's clinical profile is well established. In the ARISTOTLE trial (N=18,201), apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year, P<0.001 for noninferiority), with a 31% reduction in major bleeding [1]. These results made apixaban one of the most prescribed anticoagulants in the United States, with over 30 million prescriptions dispensed in 2023 alone.

That volume creates a cost problem. The wholesale acquisition cost for Eliquis runs roughly $550 to $600 per month. Without insurance, patients can face annual out-of-pocket expenses exceeding $6,600 [2]. Coverage through plans like Network Health can bring that number down substantially, but the specifics depend on formulary tier, copay structure, and prior authorization requirements.

How Network Health Formulary Tiers Work

Network Health, a Wisconsin-based insurer offering Medicare Advantage, Medicaid, and commercial plans, organizes its prescription drug coverage into formulary tiers. Each tier corresponds to a different cost-sharing level. Tier 1 typically holds generics with the lowest copays. Tier 2 covers preferred brands. Tier 3 and above include non-preferred brands and specialty medications with progressively higher cost-sharing.

Eliquis is a brand-name medication with no approved generic equivalent as of early 2026. On most Network Health plans, it sits on a Tier 3 (non-preferred brand) or Tier 4 placement. This means monthly copays generally range from $40 to $100 depending on the specific plan design. Some Network Health Medicare Advantage plans may place Eliquis on a preferred brand tier (Tier 2) with lower cost-sharing, particularly for plans that have negotiated more favorable rebate arrangements with Bristol-Myers Squibb and Pfizer [3].

Your plan's Summary of Benefits or formulary document, available on the Network Health member portal, is the definitive source for your tier placement. Formularies can change at the start of each plan year, and mid-year changes occasionally occur for Medicare Advantage plans with CMS approval.

Prior Authorization and Step Therapy Requirements

Some Network Health plans require prior authorization for Eliquis, particularly when the prescribed indication falls outside the most common use cases. Stroke prevention in atrial fibrillation and acute DVT/PE treatment are typically covered without prior authorization. Prophylactic use after hip or knee replacement may trigger a prior authorization review.

Step therapy is less common for Eliquis on Network Health plans. Unlike some insurers that require patients to try warfarin first, Network Health generally does not mandate step therapy for DOACs in atrial fibrillation. This aligns with the 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation, which gives DOACs a Class I recommendation over warfarin for most patients with non-valvular atrial fibrillation [4].

If a prior authorization request is denied, Network Health members have the right to appeal. For Medicare Advantage plans, the first-level appeal must be decided within 7 calendar days (72 hours for expedited requests). The CMS Medicare Appeals process provides a five-level review structure that extends to Administrative Law Judge hearings if needed.

Cost-Reduction Strategies for Eliquis on Network Health

Even with Network Health coverage, out-of-pocket costs for Eliquis can add up. Several strategies can reduce what you pay.

Manufacturer copay card. Bristol-Myers Squibb offers an Eliquis Savings Card that can reduce copays to as little as $10 per month for commercially insured patients. This card is not available to Medicare, Medicaid, or other federal program beneficiaries due to the Anti-Kickback Statute [5].

Medicare Part D coverage gap protections. The Inflation Reduction Act of 2022 capped annual out-of-pocket Part D spending at $2,000 starting in 2025. For Network Health Medicare Advantage members, this means that even if Eliquis costs push you into the coverage gap, your total prescription drug spending is capped [6]. Before this law, the catastrophic coverage threshold could leave patients paying thousands before reaching the 5% coinsurance phase.

Mail-order pharmacy. Network Health's mail-order option often provides a 90-day supply at a lower per-unit cost than retail 30-day fills. Patients filling Eliquis through mail order can save 10% to 25% compared with monthly retail pharmacy pickups.

Quantity limit exceptions. If your provider prescribes a non-standard dose requiring additional tablets, Network Health may impose quantity limits. Your prescriber can submit a quantity limit exception request with clinical documentation.

How Eliquis Compares with Covered Alternatives

Network Health formularies include several anticoagulant options. Understanding how Eliquis compares helps contextualize why coverage decisions matter.

Warfarin remains the least expensive option, with generic prices under $10 per month. The tradeoff is significant: warfarin requires regular INR monitoring (typically every 2 to 4 weeks), has numerous drug and food interactions, and carries a narrow therapeutic index. The ARISTOTLE trial demonstrated apixaban's superiority to warfarin for both efficacy and safety endpoints [1]. The American Heart Association recommends DOACs over warfarin for eligible patients [4].

Rivaroxaban (Xarelto) is another Factor Xa inhibitor. It may sit on a different formulary tier than Eliquis on Network Health plans. The ROCKET AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention (2.1% vs. 2.4% per year), but it did not demonstrate superiority for the primary endpoint [7]. A head-to-head comparison in the ARISTOPHANES study (a retrospective analysis of over 285,000 patients) suggested apixaban may have lower rates of major bleeding compared with rivaroxaban [8].

Dabigatran (Pradaxa) is a direct thrombin inhibitor. The RE-LY trial (N=18,113) showed the 150 mg dose was superior to warfarin for stroke prevention (1.11% vs. 1.69% per year), but gastrointestinal bleeding rates were higher than warfarin [9]. Network Health may cover dabigatran at a similar or different tier than apixaban.

Edoxaban (Savaysa) is prescribed less frequently but may be available on Network Health formularies. The ENGAGE AF-TIMI 48 trial (N=21,105) demonstrated non-inferiority to warfarin [10].

If your Network Health plan covers one DOAC at a lower tier than another, switching may reduce your copay without compromising clinical outcomes, though the decision should be made in consultation with your prescribing physician.

Special Populations and Coverage Considerations

Certain patient groups face unique coverage considerations with Network Health and Eliquis.

Patients with renal impairment. Apixaban is the preferred DOAC for patients with chronic kidney disease because only 27% of the drug is renally cleared, compared with 80% for dabigatran and 35% for rivaroxaban [11]. The FDA label permits a reduced dose of 2.5 mg twice daily in patients meeting two of three criteria: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. Network Health plans should cover both the 5 mg and 2.5 mg formulations, though tier placement may vary.

Patients on dual antiplatelet therapy. The AUGUSTUS trial (N=4,614) showed that apixaban plus a P2Y12 inhibitor (without aspirin) reduced bleeding and hospitalizations compared with a vitamin K antagonist-based regimen in patients with atrial fibrillation who had recent acute coronary syndrome or PCI [12]. This evidence supports apixaban use in complex cardiac patients and may strengthen prior authorization requests for Network Health members in this clinical scenario.

Cancer-associated thrombosis. The CARAVAGGIO trial (N=1,155) demonstrated apixaban was non-inferior to dalteparin for recurrent VTE in cancer patients, without increasing major gastrointestinal bleeding [13]. Network Health oncology benefit managers may require documentation of the cancer diagnosis when reviewing Eliquis prior authorizations for this indication.

What Happens If Network Health Denies Eliquis Coverage

A coverage denial is not the final word. The appeals process follows a structured path.

First, ask your prescriber to submit a coverage determination request with clinical documentation explaining medical necessity. Include relevant trial data (ARISTOTLE, AUGUSTUS, or CARAVAGGIO depending on your indication) and guideline recommendations from the ACC/AHA [4].

For Medicare Advantage members, the timeline is specific. Network Health must respond to a standard pre-service request within 72 hours. If denied, you have 60 days to file a Level 1 appeal (redetermination). The plan must decide within 7 calendar days. A second denial goes to an Independent Review Entity (Level 2), then to an Administrative Law Judge if the amount in controversy exceeds $190 (2025 threshold) [14].

For commercial plan members, the appeal process follows Wisconsin insurance regulations. External review is available through the Wisconsin Office of the Commissioner of Insurance after exhausting internal appeals.

During any appeal, ask your physician about bridge therapy. Short-term anticoagulation with enoxaparin (a low-molecular-weight heparin) or warfarin can maintain protection while coverage disputes are resolved.

The Generic Apixaban Question

Patent litigation outcomes will reshape this conversation. Bristol-Myers Squibb and Pfizer hold patents on apixaban extending into 2026, though several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) with paragraph IV certifications challenging these patents. If generic apixaban reaches the market, Network Health would likely place it on a Tier 1 or Tier 2 formulary position, reducing copays to $5 to $20 per month for most members [15].

Until generic availability is confirmed by the FDA's Orange Book, patients should plan based on current brand-name pricing. Monitor the FDA's "First Generics" announcements for updates on apixaban generic approvals.

How to Verify Your Specific Network Health Eliquis Coverage

The most reliable method: call the phone number on the back of your Network Health member ID card and ask three specific questions. What tier is Eliquis on my current formulary? Is prior authorization required for my diagnosis? What is my estimated copay for a 30-day and 90-day supply?

You can also log into the Network Health member portal, manage to the prescription drug section, and search for apixaban in the formulary lookup tool. Download your plan's Evidence of Coverage (EOC) document for the most detailed benefit description.

Your prescriber's office can run a real-time benefit check through their electronic health record system, which queries Network Health's pharmacy benefit manager directly and returns patient-specific copay estimates before the prescription is sent to the pharmacy. This avoids surprises at the counter.